These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26381180)

  • 21. Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.
    Yoshida A; Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Hiraoka N; Narita Y; Ichimura K
    Histopathology; 2019 Jan; 74(2):350-354. PubMed ID: 30221786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
    Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
    Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
    Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
    Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
    J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
    J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vaccine targeting mutant IDH1 in newly diagnosed glioma.
    Platten M; Bunse L; Wick A; Bunse T; Le Cornet L; Harting I; Sahm F; Sanghvi K; Tan CL; Poschke I; Green E; Justesen S; Behrens GA; Breckwoldt MO; Freitag A; Rother LM; Schmitt A; Schnell O; Hense J; Misch M; Krex D; Stevanovic S; Tabatabai G; Steinbach JP; Bendszus M; von Deimling A; Schmitt M; Wick W
    Nature; 2021 Apr; 592(7854):463-468. PubMed ID: 33762734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
    Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
    Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas.
    Ren F; Zhao Q; Huang L; Zheng Y; Li L; He Q; Zhang C; Li F; Maimela NR; Sun Z; Jia Q; Ping Y; Zhang Z; Chen X; Yue Y; Liu S; Cao L; Zhang Y
    Immunol Cell Biol; 2019 May; 97(5):457-469. PubMed ID: 30575118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
    Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
    Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
    Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
    PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
    Cuyàs E; Fernández-Arroyo S; Corominas-Faja B; Rodríguez-Gallego E; Bosch-Barrera J; Martin-Castillo B; De Llorens R; Joven J; Menendez JA
    Oncotarget; 2015 May; 6(14):12279-96. PubMed ID: 25980580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.